NIH Renews Contract with the Center for Immunization Research to Continue the Development and Evaluation of Life-Saving Vaccines
The Johns Hopkins Center for Immunization Research (CIR) will continue its partnership at the National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), to develop vaccines for infectious diseases of global importance (NIAID Contract 75N93019D00031; award up to $73 milion).
August is National Immunization Awareness Month (NIAM). This annual observance highlights the importance of getting recommended vaccines throughout your life. You have the power to protect yourself and your family against serious diseases like whooping cough, cancers caused by HPV, and pneumonia with vaccines.
The CIR is committed to finding vaccines to protect infants and children from infectious diseases. The RSVPed team is working in collaboration with the National Institutes of Health to develop a safe and effective RSV vaccine to protect infants and children against respiratory syncytial virus.
Celebrated in the last week of April, World Immunization Week aims to promote the use of vaccines to protect people of all ages against disease. Immunization saves millions of lives every year and is widely recognized as one of the world’s most successful and cost-effective health interventions. Yet, there are still nearly 20 million unvaccinated and under-vaccinated children in the world today.
Please join the Johns Hopkins Vaccine Initiative (JHVI) in the #VaccinesWork challenge. Take a moment to tweet about the importance of vaccines from your social media accounts using the handle @JHUCIR and the hashtag #VaccinesWork. We will tally the tweets and report our success on Vaccine Day!
Each year the Johns Hopkins Vaccine Initiative (JHVI) led by Dr. Ruth A. Karron sponsors a Vaccine Day event to showcase the breadth of vaccine related research by students and faculty at JHSPH and encourage a rich forum for collaborative discussions about future vaccine research being conducted at the school.
Karron has been working with colleagues at the National Institutes of Health on one of several efforts to develop a vaccine. She said she hopes it will be available within the next five to 10 years. A vaccine given to pregnant mothers to protect their babies could be ready sooner. The virus doesn’t evolve much, Karron said, so unlike the flu, which adapts frequently, a vaccine would not have to be updated from year to year.
Dr. Anna P. Durbin presents: The Dengue Human Infection Model: A Critical Tool for Development of a Safe and Effective Vaccine. The lecture will be presented on February 13, 2019 as part of the Johns Hopkins School of Public Health Dean’s Lecture series. Dr. Durbin is an expert in flavivirus vaccine research, leading CIR’s Team FIRE […]